Recruiting

Freedom-1

Sponsor:

Curonix LLC

Code:

NCT03877653

Conditions

Osteoarthritic Knee Pain

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Wireless neuromodulation

Study Details

Brief summary:

To demonstrate the potential benefits and risk of active sub-threshold stimulation in the treatment of chronic knee pain as compared to subjects that did not have active stimulation. Improvement will be assessed in relation to the clinical outcome measures of pain, with primary endpoint; Pain relief rate as measured by the number of subjects with greater or equal to a 50% decrease in pain on the visual analog scale, comparing baseline to the 1-month follow-up.

Conditions

Osteoarthritic Knee Pain

Study ID

NCT03877653

Start date

Sep 1, 2021

Status verified date

Feb, 2025

Completion date

Jun, 2027

Anticipated

Primary completion date

Oct, 2025

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

i. Subject is over 18 years of age; ii. Subjects with a history of chronic, function-limiting (m-MPS >6/10) knee pain from osteoarthritis of at least three months in duration with or without prior surgeries; iii. Subject has been diagnosed with Kellgren-Lawrence Grade II or III knee osteoarthritis, confirmed by X-ray studies conducted in the last year; iv. Subject has been examined and has been deemed to be an appropriate candidate for the procedure, including chronic knee pain in patients post total knee replacement (TKR); v. Subjects who are able to understand this investigation, and give voluntary, written informed consent to participate in this study; vi. Subjects who are able to co-operate with the study procedures and are willing to return to the center for all the required post-operative follow-ups; vii. Documented failure of at least two less invasive treatment modalities including physical therapy, intra-articular steroids and/or oral NSAIDS; viii. Subject has not had recent invasive surgical procedures of the knee within the following intervals in relation to the time of signing Informed Consent:- 2 weeks for steroid injection - 4 weeks for radiofrequency, cryoablation or hyaluronic acid (HA) injection ix. Subject noted good (> 75%) but only temporary relief for at least 2 hours from an infrapatellar saphenous nerve injection with local anesthetic; x. Subject is deemed to be neuro-psycho-socially appropriate for implantation therapies based of assessment of a Clinical Psychologist.

Exclusion Criteria:

xi. Significant contralateral knee pain that would influence their level of activity greater to 6 on the modified-Mankosky Pain Scale; xii. Hip or foot pain greater than knee pain; xiii. Neurogenic or vascular claudication; xiv. Subject has been diagnosed with Kellgren-Lawrence Grade IV knee osteoarthritis, confirmed by X-ray studies conducted in the last year; xv. Uncontrolled major depression or uncontrolled psychiatric disorders; xvi. Uncontrolled or acute medical illnesses including coagulopathy, renal insufficiency, chronic liver dysfunction, progressive neurological deficit, infection, unstable angina, and severe chronic obstructive pulmonary disease; xvii. Chronic severe conditions that could interfere with the interpretations of the outcome assessments for pain and bodily function (eg. Rheumatoid arthritis, severe spinal stenosis, activity-limiting cardiac disease); xviii. Women who are pregnant or planning to become pregnant, lactating; xix. Body mass index (BMI) greater than 40 (morbid obesity); xx. Subjects with multiple complaints involving concomitant knee, foot, or ankle pathology or radiculopathy, that will not be amenable to study due to the overlap of pain complaints; xxi. Subject has been examined and has been deemed to be inappropriate for the procedure based on anatomical restrictions; xxii. Lymphedema or stasis ulcers or other conditions that would compromise the surgical site; xxiii. History of adverse reaction to local anesthetic drugs; xxiv. Worker's compensation claimants; xxv. Incarcerated or has an ankle position locator; xxvi. Documented allergy to device material components; xxvii. Known or suspected substance abuse within the last 2 years; xxviii. Pacemaker or implanted defibrillator; xxix. Participation in another clinical study that could confound the results of this study; xxx. Based on the opinion of the investigator any legal or medical concerns that would preclude his/her enrollment in the study or potentially confound the results; xxxi. Any other implanted active medical devices in the same site.

Study Design

Enrollment

100 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Interventional

Single arm, active stimulation

placebo comparator: Placebo

When receiving sham stimulation, devices will be programmed to not actively deliver electrical stimulation but still deplete battery life to maintain blinding. Subjects will have to recharge batteries similar to receiving active stimulation.

Sites will not have access to WaveCrest programmer. Study devices can only be programmed by Stimwave representatives.

Interventions

Wireless neuromodulation

A needle and catheter are carefully inserted near the enervated nerve. The stimulator is then placed through the catheter close to the nerve. The proximal end of the stimulator is then sutured underneath the skin to prevent migration.

Primary outcome measure

  • Responder rate [ Time Frame: 1 month ]

Central Contacts and Locations

Central contacts

Locations

Western Clinical Research

Recruiting

Placentia, California, United States, 92870

Contacts

Principal Investigator:

Albert Lai, MD

Colorado Pain Care, LLC

Recruiting

Denver, Colorado, United States, 80222

Contacts

Principal Investigator:

Robert Moghim, MD

Holy Cross Hospital, Inc

Recruiting

Fort Lauderdale, Florida, United States, 33308

Contacts

Principal Investigator:

Paul Wu, MD

Florida Joint Care Institute

Recruiting

Trinity, Florida, United States, 34655

Contacts

Principal Investigator:

Aaron Mates, DO

Southern Pain and research

Recruiting

Jasper, Georgia, United States, 30143

Contacts

Principal Investigator:

Jordan Tate, MD

Vista Clinical Research/Summit Spine & Joint Centers

Recruiting

Newnan, Georgia, United States, 30265

Contacts

Principal Investigator:

Sandeep Vaid, DO

Desert Orthopaedic Center

Recruiting

Las Vegas, Nevada, United States, 89149

Contacts

Principal Investigator:

Sungkook park, MD

Orthopedic Associates of Southwest Ohio

Recruiting

Dayton, Ohio, United States, 45459

Contacts

Principal Investigator:

Jonathan Silverman, MD

Premier Pain Treatment

Recruiting

Loveland, Ohio, United States, 45140

Contacts

Principal Investigator:

Michael Danko, MD

Kettering Health

Recruiting

Miamisburg, Ohio, United States, 45429

Contacts

Principal Investigator:

Nirmala Abraham, MD

Austin Orthopedic Institute

Recruiting

Austin, Texas, United States, 78759

Principal Investigator:

Earl Kilbride, DO

Performance pain and sports medicine

Recruiting

Houston, Texas, United States, 77027

Contacts

Principal Investigator:

Matthias Wiederholz, MD

Advanced Spine and Pain Center

Recruiting

San Antonio, Texas, United States, 78240

Contacts

Principal Investigator:

Ellen Lin, MD

More Information

Sponsor

Curonix LLC

Last update posted

Feb 13, 2025

Last verified

Feb, 2025

Keywords

  • PNS
  • Chronic
  • Pain
  • Wireless
  • Neuromodulation
  • knee
  • osteoarthritic
  • peripheral nerve stimulation
  • infra patellar saphenous

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Curonix LLC on 2025-02-13.